Mini-Oral Session

[MO25] Mini-Oral Session 25　Translational Research / Clinical Pharmacology 4（Miscellaneous）
【E】

Fri. Feb 18, 2022 2:05 PM - 2:45 PM Room 8 (Sakura, 1F, Kyoto International Conference Center)

Chair：Chiyo K. Imamura（Advanced Cancer Translational Research Institute, Showa University），Yoshitsugu Horio（Department of Outpatient Services, Aichi Cancer Center Hospital）

+Add all to schedule

[MO25-1] Prognostic values of SII index and systemic inflammatory markers in advanced cancer received palliative chemotherapy

^○Chanchai Charonpongsuntorn, Supitchaya Phirom, Panunat Muangnoi (Medical Oncology Unit, Department of Internal Medicine, Srinakharinwirot University)

[MO25-2] Phase I study of tiragolumab in combination with atezolizumab in Japanese patients with advanced solid tumors

^○Noboru Yamamoto¹, Takafumi Koyama³, Jun Sato³, Yoshida Tatsuya³, Kazuki Sudo³, Satoru Iwasa³, Shunsuke Kondo³, Kan Yonemori³, Toshio Shimizu³, Atsuko Kawasaki², Kyoko Satake², Shoyo Shibata² (1.Department of Experimental Therapeutics, 2.Chugai Pharmaceutical Co., Ltd., 3.Department of Experimental Therapeutics, National Cancer Center Hospital)

[MO25-3] Regorafenib-induced erythema multiforme is associated with HLA-C01:02* and HLA-B46:01* in Japanese cancer patients

^○Natsumi Matsumoto¹, Kosuke Takeshima¹, Yutaro Kubota², Hiroo Ishida², Takuya Taunoda², Yasutsuna Sasaki², Ken-Ichi Fujita¹ (1.Division of Cancer Genome and Pharmacotherapy, Showa University School of Pharmacy, 2.Division of Medical Oncology, Showa University School of Medicine)

[MO25-4] Exploratory Analysis of HER2 Extracellular Domain in HER2 Positive Gastric Cancer treated with SOX plus Trastuzumab

^○Shuichi Hironaka¹, Takeru Wakatsuki², Naoki Ishizuka³, Keiko Minashi¹, Shigenori Kadowaki⁴, Masahiro Goto^1,5, Hirokazu Shoji⁶, Hidekazu Hirano⁶, Izuma Nakayama², Hiroki Osumi², Mariko Ogura², Keisho Chin², Kensei Yamaguchi², Daisuke Takahari² (1.Clinical Trial Promotion Department, Chiba Cancer Center, 2.Department of Gastrointestinal Medical Oncology, Cancer Institute Hospital of JFCR, 3.Department of Clinical Trial Planning and Management, 4.Department of Clinical Oncology, Aichi Cancer Center, 5.Department of Chemotherapy, Osaka Medical University, 6.Department Gastrointestinal Medical Oncology, National Cancer Center Hospital)

[MO25-5] A Phase 1 Study to Compare Formulations and Evaluate the Effect of Food on Pimitespib in Patients with Solid Tumors

^○Kazuo Kasahara¹, Yoshito Komatsu², Tsuneo Shimokawa³, Kohei Akiyoshi⁴, Masato Karayama⁵, Akihiko Shimomura⁶ (1.Department of Respiratory Medicine, Kanazawa University Hospital, 2.Department of Cancer Center, Hokkaido University Hospital, 3.Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, 4.Department of Medical Oncology, Osaka City General Hospital, 5.Department of Chemotherapy, Hamamatsu University School of Medicine, 6.Department of Breast and Medical Oncology, National Center for Global Health and Medicine)